YAP activation is a key mediator of therapy resistance in multiple cancers, including HCC.23,24 We identified a dysadherin/YAP axis that drives sorafenib resistance by promoting YAP nuclear localization and transcriptional activity, thereby enhancing stemness and survival under treatment stress. Here, FXYD5 is linked to cancer.